Development of Magnetic Nanoparticle-based Enrichment Techniques and Mass Spectrometry Methods for Quantification of the Clinical Biomarker Cardiac Troponin I

dc.contributor.advisorLee, Sang Boken_US
dc.contributor.authorSchneck, Nicoleen_US
dc.contributor.departmentChemistryen_US
dc.contributor.publisherDigital Repository at the University of Marylanden_US
dc.contributor.publisherUniversity of Maryland (College Park, Md.)en_US
dc.date.accessioned2017-01-24T06:44:01Z
dc.date.available2017-01-24T06:44:01Z
dc.date.issued2016en_US
dc.description.abstractHuman cardiac troponin I (cTnI) in serum is a well-known clinical biomarker for cardiac tissue damage and is used for diagnosing myocardial infarction. Unfortunately, commercial cTnI immunoassays from different manufacturers can produce significantly different measurement results for the same sample. In order to improve the comparability of these measurements, clinical cTnI immunoassays need to be standardized. Ultimately, the goal of this work was to develop an isotope dilution-liquid chromatography-mass spectrometry (ID-LC-MS/MS) reference measurement procedure that could be used to assign concentration values to cTnI reference materials. However, given that most serum protein biomarkers are low abundant, enrichment was mandatory to successfully quantify cTnI at clinically significant concentrations (≈ 1-10 ng/mL). As such, the specific aim of this work was to develop enrichment techniques and an ID-LC-MS/MS method to quantify cTnI in patient serum samples. In order to achieved the required LC-MS/MS sensitivity, novel enrichment strategies were investigated to selectively isolate cTnI from serum and plasma. Silica coated magnetic nanoparticles were synthesized and conjugated with antibodies to act as immunoaffinity carriers. Magnetic nanoparticles were selected due to their variable surface modifications, high binding capacity, and the fact that they can be easily isolated using a magnet. After optimizing the enrichment and digestion procedures, isotopically labeled cTnI proteins were used as an internal standard for ID-LC-MS/MS analysis of cTnI to compensate for variations in the sample preparation. Finally, the developed LC-MS/MS-based assay was applied to measure cTnI concentrations in patient plasma samples. Effective enrichment methods proved to be crucial for achieving quantification of cTnI by ID-LC-MS/MS. To this end, a complementary ID-LC-MS/MS method was also developed to evaluate different antibody immobilization strategies and magnetic particle types as part of the method optimization. Overall, this work demonstrates significant improvements in magnetic particle enrichment techniques and LC-MS/MS detection for the analysis of cTnI in patient samples.en_US
dc.identifierhttps://doi.org/10.13016/M2WR7Z
dc.identifier.urihttp://hdl.handle.net/1903/18991
dc.language.isoenen_US
dc.subject.pqcontrolledChemistryen_US
dc.subject.pqcontrolledBiochemistryen_US
dc.subject.pquncontrolledBioanalytical methodsen_US
dc.subject.pquncontrolledCardiac troponin Ien_US
dc.subject.pquncontrolledImmunoaffinity enrichmenten_US
dc.subject.pquncontrolledMass spectrometryen_US
dc.subject.pquncontrolledNanoparticlesen_US
dc.subject.pquncontrolledProtein biomarkersen_US
dc.titleDevelopment of Magnetic Nanoparticle-based Enrichment Techniques and Mass Spectrometry Methods for Quantification of the Clinical Biomarker Cardiac Troponin Ien_US
dc.typeDissertationen_US

Files

Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Schneck_umd_0117E_17672.pdf
Size:
3.97 MB
Format:
Adobe Portable Document Format